Chen Muxiong, Fang Wenpan, Wu Xinkai, Bian Suchen, Chen Guangdi, Lu Liqin, Weng Yu
Institute of Environmental Health, Zhejiang University School of Medicine, Hangzhou, China.
Research Center of Molecular Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Oncotarget. 2017 Apr 27;8(43):75336-75349. doi: 10.18632/oncotarget.17454. eCollection 2017 Sep 26.
Previous studies have indicated an association between the genetic variant in pre-miR-27a rs895819 with A->G transition and cancer risk; however, the results remain inconsistent and somehow conflicting in different cancers. Therefore, to obtain a more reliable conclusion, we performed an update meta-analysis by searching PubMed database or other databases. Odds ratio (ORs) and 95% confidence interval (CIs) were calculated to evaluate cancer risk. A total of 34 case-control studies involving 15,388 cases and 18,704 controls were included. The results showed that rs895819 was associated with an increased cancer risk (GG AA/AG: OR = 1.15, 95% CI = 1.02-1.29). Furthermore, stratification analyses revealed an association of rs895819 with increased cancer risk among Asians (GG AA: OR = 1.17, 95% CI = 1.01-1.36; GG AA/AG: OR = 1.18, 95% CI = 1.03-1.35), but not Caucasians. Interestingly, the [G] allele of rs895819 was significantly associated with decreased risk of breast cancer (G A: OR = 0.91, 95% CI = 0.86-0.97). However, rs895819 was associated with increased risk of colorectal cancer (GG AA: OR = 1.56, 95% CI = 1.31-1.85; GG AA/AG: OR = 1.53, 95% CI = 1.30-1.79; G A: OR = 1.19, 95% CI = 1.09-1.30) and lung cancer (GG AA/AG: OR = 1.43, 95% CI = 1.00-2.04). In addition, no association was found between rs895819 and risk of gastric cancer or esophageal cancer. In conclusion, our findings suggest distinct effects of rs895819 on risk of different cancers, and future well-designed studies with large samples are required to further validate our results.
先前的研究表明，前体微小RNA-27a（pre-miR-27a）中rs895819的A→G转换基因变异与癌症风险之间存在关联；然而，在不同癌症中的结果仍不一致且存在一定冲突。因此，为了得出更可靠的结论，我们通过检索PubMed数据库及其他数据库进行了一项更新的荟萃分析。计算优势比（OR）和95%置信区间（CI）以评估癌症风险。共纳入34项病例对照研究，涉及15388例病例和18704例对照。结果显示，rs895819与癌症风险增加相关（GG对AA/AG：OR = 1.15，95% CI = 1.02 - 1.29）。此外，分层分析显示rs895819与亚洲人癌症风险增加相关（GG对AA：OR = 1.17，95% CI = 1.01 - 1.36；GG对AA/AG：OR = 1.18，95% CI = 1.03 - 1.35），但与高加索人无关。有趣的是，rs895819的[G]等位基因与乳腺癌风险降低显著相关（G对A：OR = 0.91，95% CI = 0.86 - 0.97）。然而，rs895819与结直肠癌风险增加相关（GG对AA：OR = 1.56，95% CI = 1.31 - 1.85；GG对AA/AG：OR = 1.53，95% CI = 1.30 - 1.79；G对A：OR = 1.19，95% CI = 1.09 - 1.30）和肺癌风险增加相关（GG对AA/AG：OR = 1.43，95% CI = 1.00 - 2.04）。此外，未发现rs895819与胃癌或食管癌风险之间存在关联。总之，我们的研究结果表明rs895819对不同癌症风险有不同影响，未来需要设计良好的大样本研究来进一步验证我们的结果。
